Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pm-Pac + cisplatin + tislelizumab as first-line therapy for unresectable advanced ESCC
ChiCTR2400088576Phase 2Completed
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, cisplatin and tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: objective response rate. Started Aug 2024; status: completed.
02
Drugs
paclitaxelcisplatintislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400088576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088576.